|Description||IRL-1620 significantly enhanced delivery and effectiveness of paclitaxel in an animal model of breast cancer. IRL-1620 together with IRL-1038 (Prod. No. ALX-155-007) is an indispensable pharmacological tool to assess the participation of the ETB receptor in some pathophysiological phenomena, by selectively stimulating ETB receptor-mediated responses in various pathophysiological models established in vitro and in vivo.|
|Solubility||Insoluble in water. Dissolve the content with > pH 8.5 buffer.|
|Storage||Store at -20°C.|
|Note||This peptide is most potent and specific ligand for the ETB receptor (KiETA/KiETB=120 000) as judged by the Ki values for ETA (1.9 µM) and ETB (16 pM) receptors. IRL1620 (10-9-10-7 µM) induced contraction of the guinea pig tracheal with a comparable potency to those of ET-1 or ET-3.|
For more documents, please visit "Technical Support".